Alexey Repik has worked in the field of healthcare and pharmaceuticals since his youth. In 1994, a 15-year-old Repik, who grew up in a family of scientists, graduated from the prestigious Moscow gymnasium externally. However, he could not immediately pass the entrance exams to the historical faculty of Moscow State University. Then he was disappointed in the history and decided to study the economy – but before the entrance examinations to the Higher School of Economics there was still a year. Therefore, Repik went to work in the planning and economic department of the city hospital number 29.
The head of the department was often sick, and many important tasks fell on the shoulders of a 16-year-old employee. In particular, he had to represent in the Moscow Department of Health an estimate of the purchase of medicines and equipment for the hospital. Thanks to this, he began to understand how the pharmaceutical market operates.
A year later Repik entered the Higher School of Economics, but did not leave work in the hospital. And three years later he was offered to go to a small distribution company Rosmedkomplekt, whose office was located in the hospital. In the first year of work of the young manager, the company’s turnover grew tens of times. Thanks to a good level of English and fresh knowledge gained at the Higher School of Economics, he was able to establish strong contacts with large foreign pharmaceutical companies. The country’s economy operated on a new market scheme, which allowed the talented student to have an advantage over the more experienced specialists who were educated in Soviet times.
As a result, Repika was promoted to the position of director of sales. In 2001, he was promised to become a co-owner of the company and be appointed general director. But in 2000 in “Rosmedkomplekt” the composition of co-owners was changed, conflicts arose, after which Repk was accused of losses and was fired with a scandal.
In the summer of 2001 Repik sold the car, borrowed money from his mother and registered his own company “R-Pharm.” Before the end of the Higher School of Economics at that time there were two years – Repik received a diploma in economics and business management only in 2003. “R-Pharm” began to compete with “Rosmedkomplekt” in the market of supply of drugs to hospitals, and by 2005 won a confident victory. “Rosmedkomplekt” was forced to withdraw from the market, having passed the liquidation procedure.
In 2006, the state program of additional medicinal provision for privileged categories of citizens began to operate in Russia. Within the framework of this program, expensive long-term courses of treatment were paid from the budget. “R-Pharm” won a large number of tenders for the supply of drugs under this program. This was a breakthrough for the company, it gained access to budgetary funds.
Repik himself stated in an interview that this can not be called a miracle – he said he had calculated all the prospects in advance. Competently adjusted work with suppliers allowed him to purchase medicines at a bargain price, which, in turn, ensured victory at government tenders.
Repik maintains that he is avoiding politics and does not understand the laws by which it exists. His element – the economy and business. However, as a major supplier of drugs, he repeatedly had to meet with Russian President Vladimir Putin, Prime Minister Dmitry Medvedev, Moscow Mayor Sergei Sobyanin. At these meetings, he told the leaders of the country about the achievements and needs of the pharmaceutical industry. Repik has the status of a member of the Public Chamber of the Russian Federation, a member of the Economic Council under the President of the Russian Federation, co-chairman of the All-Russian public organization “Business Russia”.
In 2016, Repik took 116th place in the ranking of 200 richest businessmen in Russia, compiled by Forbes magazine. His condition is estimated at $ 900 million. In recent years Repik has retained Russian citizenship, but lives mostly in the United States. Repku still owns 100 percent of the shares of R-Pharm, he did not have business partners.
In the state of “R-Pharm” today there are more than 2,5 thousand employees. The company has its own production facilities for the production of medicines, conducts its own and partner research programs in Russia and abroad. The company also prepares specialists in the pharmaceutical industry. In addition to Russia, R-Pharm operates in the CIS countries, and also participates in projects in the US, Switzerland, Germany, France, Japan, India and China. In 2016, R-Pharm took 166th place in the ranking of the largest Russian companies, compiled by RBC. The annual revenue of the company is estimated at 63 billion rubles.